| Literature DB >> 23603949 |
Yahia Nasser Mabkhot1, Nabila Abdelshafy Kheder, Ahmad M Farag.
Abstract
A series of thieno[2,3-b]thiophene moiety-containing bis-cyanopyrazoles 5a-c, bis-aminopyrazole 9 and bis-pyridazine derivatives 11 were synthesized and evaluated in vitro for their antimicrobial potential. The antimicrobial activity of some selected products was evaluated and showed good results. 5,5'-(3,4-Dimethylthieno[2,3-b]thiophene-2,5-diyl)bis(3-acetyl-1-(4-chlorophenyl)-1H-pyrazole-4-carbonitrile) (5d) was found to be more potent than the standard drug amphotericin B against Geotricum candidum and equipotent to amphotericin B against Syncephalastrum racemosum. In addition, it was found to be equipotent to the standard drug Penicillin G against Staphylococcus aureus. Moreover, it was more potent than the standard drug streptomycin against Pseudomonas aeruginosa and Escherichia coli.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23603949 PMCID: PMC6270460 DOI: 10.3390/molecules18044669
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Synthesis of bis-cyanopyrazole derivatives 5a–g.
Scheme 2Synthesis of thieno[2,3-b]thiophene 8 and bis-aminopyrazole 9.
Scheme 3Synthesis of bis-pyridazine 11.
Antifungal activities of the synthesized compounds 5c,d and 11.
| 17.3 ± 0.4 | 21.3 ± 0.4 | NA | 14.8 ± 0 | |
| 22.4 ± 0.5 | 29.7 ± 0.2 | NA | 19.8 ± 0.8 | |
| 18.9 ± 0.3 | 23.4 ± 0.4 | NA | 16.5 ± 0.2 | |
| 23.7 ± 0.1 | 28.7 ± 0.2 | 25.4 ± 0.1 | 19.7 ± 0.2 | |
NA: No activity, data are expressed in the form of mean ± SD.
Antibacterial activities of the synthesized compounds 5c,d and 11.
| 18.6 ± 0.3 | 20.9 ± 0.5 | 17.4 ± 0.2 | 20.3 ± 0.4 | |
| 23.8 ± 0.5 | 27.4 ± 0.6 | 20.7 ± 0.2 | 26.8 ± 0.2 | |
| 20.4 ± 0.4 | 23.1 ± 0.2 | 19.6 ± 0.1 | 22.2 ± 0.5 | |
| 23.8 ± 0.2 | 32.4 ± 0.3 | - | - | |
|
| - | - | 20.3 ± 0.1 | 24.9 ± 0.3 |
NA: No activity, data are expressed in the form of mean ± SD. Mean zone of inhibition in mm ± Standard deviation beyond well diameter (6 mm) produced on a range of environmental and clinically pathogenic microorganisms using (5 mg/mL) concentration of tested samples.
Figure 1Antifungal activities of the synthesized compounds 5c,d and 11 against micoorganisms—1. Aspergillus fumgatus; 2. Geotrichum candidum; 3. Candida albicans; 4. Syncephalastrum racemosum.
Figure 2Antibacterial activities of the synthesized compounds 5c,d and 11 against micoorganisms—1. Staphylococcus aureus; 2. Bacillis subtilis; 3. Pseudomonas aeruginosa; 4. Escherichia coli.